The long-term effect of switching from cyclosporin A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1909-1916

  François, Hélène ^a   Dürrbach, Antoine ^a,c   Amor, Mounia ^a   Djeffal, Rachid ^a   Kriaa, Fayçal ^a   Paradis, Valérie ^b   Bedossa, Pierre ^b   Charpentier, Bernard ^a,c  

^a BICÊTRE HOSPITAL   (France)

^b Anatomopathology Unit   (France)

^c INSERM   (France)

Author keywords

Cyclosporin A; Graft dysfunction; Mycophenolate mofetil; Substitution

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOSINATE DEHYDROGENASE INHIBITOR; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT ERYTHROPOIETIN; STEROID;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CANCER; CHRONIC DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DETERIORATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GOUT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; INFECTION; INTERMETHOD COMPARISON; KIDNEY ALLOGRAFT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADULT; CARDIOVASCULAR ABNORMALITIES; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0042384855     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg250     Document Type: Article

References (20)

1. Canadian Multicentre Transplant Study Group. A randomised clinical trial of cyclosporine in cadaveric renal transplantation at three years. N Engl J Med 1986; 314: 1219-1225
2. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: 5 years follow-up of a multicentre trial. Lancet 1987; 2: 506-507
3. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037
4. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325
5. Sollinger HW, for the US Renal Transplant Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232
6. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77-84
7. Weir MR, Anderson L, Fink JC. A novel approach of chronic allograft nephropathy. Transplantation 1997; 64: 1706-1710
8. Weir MR, Ward MT, Blahut SA, Klassen DK. Long-term impact of discontinued or reduced calcineurine inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573
9. Ducloux D, Fournier V, Bresson-Vautrin C. Mycophenolate mofetil in renal transplant recipients with cyclosporine associated nephrotoxicity. Transplantation 1998; 65: 1504
10. Houde I, Isenring P, Boucher D et al. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation. Transplantation 2000; 70: 1251-1253
11. Schrama YC, Joles JA, van Tool A, Boer P, Koomans HA, Hene RJ. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000; 69: 376-383
12. Sévaux de RGL, Smak Gregoor PJH. Withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: a randomised study. AST Eighteenth Annual Meeting 1999: Abstract 935
13. Van Buren DH, Burke JF, Lewis RM. Renal function in patients receiving long term cyclosporine therapy. J Am Soc Nephrol 1994; 4: S17
14. Hueso M, Bover J, Seron D et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66: 1727-1731
15. Fujihara CK, Avancini DM, Costa Malheiros DMA, De Zatz R, Lourdes Noronha I. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510-1519
16. Romero F, Rodriguez-Iturbe B, Parra G, Gonzales L, Herrera-Acosta J, Tapia E. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945-955
17. Cherid B, Vincent M, McGregor B, Melin M, Hadj-Aissa A. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61
18. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int 1995; [Suppl 52]: S56-S59
19. Van Besouw NM, V D Mast BJ, Smak Gregoor PJ. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 1999; 14: 2710-2713
20. Van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266